First dose in children: Physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 39, Issue 2, 2012, Pages 195-203

  Strougo, Ashley ^a,b   Eissing, Thomas ^c   Yassen, Ashraf ^b   Willmann, Stefan ^c   Danhof, Meindert ^a   Freijer, Jan ^d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b Astellas Pharma Global Development   (Netherlands)

^c BAYER AG   (Germany)

^d CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

Allometric scaling; Bridging; Extrapolation; Pediatrics; Physiologically based pharmacokinetic models; Scaling

Indexed keywords

LIVER ENZYME; MORPHINE; PARACETAMOL;

ADOLESCENT; ADULT; ALLOMETRY; ARTICLE; CHILD; CHILD CARE; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE CALCULATION; DRUG CLEARANCE; DRUG RESEARCH; DRUG SCREENING; ENZYME ACTIVITY; HUMAN; INTERMETHOD COMPARISON; LIPOPHILICITY; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCHOOL CHILD;

ACETAMINOPHEN; ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HUMANS; INFANT; INFANT, NEWBORN; METABOLIC CLEARANCE RATE; MORPHINE;

EID: 84861483762     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-012-9241-9     Document Type: Article

References (21)

1. European Medicines Agency (2007) ICH Topic E11 clinical investigation on medicinal products in the paediatric population. CPMP/ICH/2711/99. 2007
2. Edginton AN, Schmitt W, Willmann S (2006) Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 45:1013-1034 (Pubitemid 44436004)
3. Nestorov I (2003) Whole body pharmacokinetic models. Clin Pharmacokinet 42:883-908
4. Johnson TN, Rostami-Hodjegan A, Tucker GT (2006) Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 45:931-956 (Pubitemid 44299829)
5. West GB, Brown JH, Enquist BJ (1997) A general model for the origin of allometric scaling laws in biology. Science 276:122-126 (Pubitemid 27161259)
6. Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303-332 (Pubitemid 351738156)
7. Bouillon-Pichault M, Jullien V, Bazzoli C, Pons G, Tod M (2011) Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4. J Pharmacokinet Pharmacodyn 38:25-40
8. Tod M, Jullien V, Pons G (2008) Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 47:231-243 (Pubitemid 351367434)
9. Anderson BJ, Pons G, Autret-Leca E, Allegaert K, Boccard E (2005) Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. Paediatr Anaesth 15: 282-292 (Pubitemid 40462802)
10. Anand KJ, Anderson BJ, Holford NH, Hall RW, Young T, Shephard B, Desai NS, Barton BA (2008) Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth 101: 680-689
11. Zhao L, Pickering G (2011) Paracetamol metabolism and related genetic differences. Drug Metab Rev 43:41-52
12. Glare PA, Walsh TD (1991) Clinical pharmacokinetics of morphine. Ther Drug Monit 13:1-23
13. Willmann S, Edginton AN, Coboeken K, Ahr G, Lippert J (2009) Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clin Pharmacol Ther 86:634-643
14. International Commission on Radiological Protection (ICRP) (2002) Basic anatomical and physiological data for use in radiological protection: reference values. ICRP publication 89. Elsevier Science, Amsterdam
15. Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NH (2004) Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth 92:208-217 (Pubitemid 38159658)
16. Knibbe CA, Krekels EH, van den Anker JN, DeJongh J, Santen GW, van DM, Simons SH, van Lingen RA, Jacqz-Aigrain EM, Danhof M, Tibboel D (2009) Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 48:371-385
17. Eissing T, Kuepfer L, Becker C, Block M, Coboeken K, Gaub T, Goerlitz L, Jaeger J, Loosen R, Ludewig B, Meyer M, Niederalt C, Sevestre M, Siegmund HU, Solodenko J, Thelen K, Telle U, Weiss W, Wendl T, Willmann S, Lippert J (2011) A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front Physiol 2:4
18. Edginton AN, Schmitt W, Voith B, Willmann S (2006) A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet 45:683-704 (Pubitemid 43990570)
19. Edginton AN, Willmann S (2006) Physiology-based versus allometric scaling of clearance in children; an eliminating process based comparison. Paediatr Perinat Drug Ther 7:146-153 (Pubitemid 46010017)
20. Pang KS, Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653 (Pubitemid 8253670)
21. Mashayekhi SO, Sattari MR, Routledge PA (2010) Evidence of active transport involvement in morphine transport via MDCKII and MDCK-PGP cell lines. Res Pharm Sci 5:99-106